JP2007502843A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007502843A5 JP2007502843A5 JP2006524092A JP2006524092A JP2007502843A5 JP 2007502843 A5 JP2007502843 A5 JP 2007502843A5 JP 2006524092 A JP2006524092 A JP 2006524092A JP 2006524092 A JP2006524092 A JP 2006524092A JP 2007502843 A5 JP2007502843 A5 JP 2007502843A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- alkyl
- crr
- butyl
- propyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 100
- 125000003342 alkenyl group Chemical group 0.000 claims 44
- 125000000304 alkynyl group Chemical group 0.000 claims 44
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 41
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 36
- 150000001875 compounds Chemical class 0.000 claims 33
- 229910052799 carbon Inorganic materials 0.000 claims 32
- -1 cyclic acetal Chemical class 0.000 claims 31
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 30
- 229910052760 oxygen Inorganic materials 0.000 claims 30
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 30
- 125000005842 heteroatom Chemical group 0.000 claims 29
- 229910052717 sulfur Inorganic materials 0.000 claims 29
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 28
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 28
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 27
- 125000002837 carbocyclic group Chemical group 0.000 claims 26
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims 22
- 125000000623 heterocyclic group Chemical group 0.000 claims 20
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 20
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 19
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 16
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 11
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 11
- 125000004076 pyridyl group Chemical group 0.000 claims 7
- 230000000694 effects Effects 0.000 claims 6
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 5
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 5
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 5
- 125000003118 aryl group Chemical group 0.000 claims 5
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- 125000001041 indolyl group Chemical group 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 125000002757 morpholinyl group Chemical group 0.000 claims 5
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 claims 5
- 125000004429 atom Chemical group 0.000 claims 4
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 4
- 125000002541 furyl group Chemical group 0.000 claims 4
- 125000000842 isoxazolyl group Chemical group 0.000 claims 4
- 125000002971 oxazolyl group Chemical group 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000003373 pyrazinyl group Chemical group 0.000 claims 4
- 125000003226 pyrazolyl group Chemical group 0.000 claims 4
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 4
- 125000001544 thienyl group Chemical group 0.000 claims 4
- 201000001320 Atherosclerosis Diseases 0.000 claims 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 3
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 3
- 208000006673 asthma Diseases 0.000 claims 3
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 claims 3
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 claims 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 125000001188 haloalkyl group Chemical group 0.000 claims 3
- 125000002883 imidazolyl group Chemical group 0.000 claims 3
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 3
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 3
- 125000001786 isothiazolyl group Chemical group 0.000 claims 3
- 201000006417 multiple sclerosis Diseases 0.000 claims 3
- 201000008383 nephritis Diseases 0.000 claims 3
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 claims 3
- 125000003386 piperidinyl group Chemical group 0.000 claims 3
- 125000002098 pyridazinyl group Chemical group 0.000 claims 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 3
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 3
- 125000003831 tetrazolyl group Chemical group 0.000 claims 3
- 125000000335 thiazolyl group Chemical group 0.000 claims 3
- 125000004306 triazinyl group Chemical group 0.000 claims 3
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 claims 2
- 206010001889 Alveolitis Diseases 0.000 claims 2
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims 2
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 claims 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 2
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 claims 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims 2
- 125000005512 benztetrazolyl group Chemical group 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 206010009887 colitis Diseases 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 claims 2
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 230000003589 nefrotoxic effect Effects 0.000 claims 2
- 231100000381 nephrotoxic Toxicity 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 2
- 208000037803 restenosis Diseases 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- MHCVCKDNQYMGEX-UHFFFAOYSA-N 1,1'-biphenyl;phenoxybenzene Chemical group C1=CC=CC=C1C1=CC=CC=C1.C=1C=CC=CC=1OC1=CC=CC=C1 MHCVCKDNQYMGEX-UHFFFAOYSA-N 0.000 claims 1
- 125000006022 2-methyl-2-propenyl group Chemical group 0.000 claims 1
- 206010002329 Aneurysm Diseases 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 claims 1
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 claims 1
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 claims 1
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 claims 1
- 102100023702 C-C motif chemokine 13 Human genes 0.000 claims 1
- 101710112613 C-C motif chemokine 13 Proteins 0.000 claims 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 claims 1
- 102100032366 C-C motif chemokine 7 Human genes 0.000 claims 1
- 101710155834 C-C motif chemokine 7 Proteins 0.000 claims 1
- 102100034871 C-C motif chemokine 8 Human genes 0.000 claims 1
- 101710155833 C-C motif chemokine 8 Proteins 0.000 claims 1
- 102000004497 CCR2 Receptors Human genes 0.000 claims 1
- 108010017312 CCR2 Receptors Proteins 0.000 claims 1
- 102000004274 CCR5 Receptors Human genes 0.000 claims 1
- 108010017088 CCR5 Receptors Proteins 0.000 claims 1
- 108010055166 Chemokine CCL5 Proteins 0.000 claims 1
- 102000009410 Chemokine receptor Human genes 0.000 claims 1
- 108050000299 Chemokine receptor Proteins 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 101150004219 MCR1 gene Proteins 0.000 claims 1
- 101000978374 Mus musculus C-C motif chemokine 12 Proteins 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010037660 Pyrexia Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 208000029028 brain injury Diseases 0.000 claims 1
- 210000000748 cardiovascular system Anatomy 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 125000003971 isoxazolinyl group Chemical group 0.000 claims 1
- AEUKDPKXTPNBNY-XEYRWQBLSA-N mcp 2 Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)C1=CC=CC=C1 AEUKDPKXTPNBNY-XEYRWQBLSA-N 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 0 CC1C(C)CN(*)C1 Chemical compound CC1C(C)CN(*)C1 0.000 description 5
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49694703P | 2003-08-21 | 2003-08-21 | |
| US60/496,947 | 2003-08-21 | ||
| US10/923,619 | 2004-08-19 | ||
| US10/923,619 US7163937B2 (en) | 2003-08-21 | 2004-08-19 | Cyclic derivatives as modulators of chemokine receptor activity |
| PCT/US2004/027196 WO2005021500A1 (en) | 2003-08-21 | 2004-08-20 | Cyclic derivatives as modulators of chemokine receptor activity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007502843A JP2007502843A (ja) | 2007-02-15 |
| JP2007502843A5 true JP2007502843A5 (enExample) | 2007-08-09 |
| JP4795238B2 JP4795238B2 (ja) | 2011-10-19 |
Family
ID=34228609
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006524092A Expired - Fee Related JP4795238B2 (ja) | 2003-08-21 | 2004-08-20 | ケモカインレセプター活性のモジュレータとしての環状誘導体 |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US7163937B2 (enExample) |
| EP (1) | EP1656345B1 (enExample) |
| JP (1) | JP4795238B2 (enExample) |
| KR (1) | KR101120338B1 (enExample) |
| AU (1) | AU2004268968B2 (enExample) |
| BR (1) | BRPI0413713A (enExample) |
| CA (1) | CA2536384C (enExample) |
| DK (1) | DK1656345T3 (enExample) |
| ES (1) | ES2437104T3 (enExample) |
| HR (1) | HRP20131048T1 (enExample) |
| IL (2) | IL173824A (enExample) |
| IS (1) | IS8313A (enExample) |
| MX (1) | MXPA06001819A (enExample) |
| NO (1) | NO335946B1 (enExample) |
| NZ (1) | NZ545317A (enExample) |
| PL (1) | PL1656345T3 (enExample) |
| PT (1) | PT1656345E (enExample) |
| RS (1) | RS20060116A (enExample) |
| RU (1) | RU2006108867A (enExample) |
| SI (1) | SI1656345T1 (enExample) |
| WO (1) | WO2005021500A1 (enExample) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005506949A (ja) | 2000-12-20 | 2005-03-10 | ブリストル−マイヤーズ・スクイブ・ファーマ・カンパニー | ケモカイン受容体の調節剤としてのジアミン |
| AR035773A1 (es) | 2000-12-20 | 2004-07-14 | Bristol Myers Squibb Pharma Co | Compuestos diamino ciclico, composicion farmaceutica y su uso en la fabricacion de un medicamento util para modular la actividad de una quimioquina |
| WO2003075853A2 (en) | 2002-03-08 | 2003-09-18 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
| US7291615B2 (en) | 2003-05-01 | 2007-11-06 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
| US7163937B2 (en) * | 2003-08-21 | 2007-01-16 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
| US7317019B2 (en) * | 2003-08-21 | 2008-01-08 | Bristol Myers Squibb Co. | N-alkylated diaminopropane derivatives as modulators of chemokine receptor activity |
| US7825244B2 (en) | 2005-06-10 | 2010-11-02 | Janssen Pharmaceutica Nv | Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis |
| US8071768B2 (en) | 2005-06-10 | 2011-12-06 | Janssen Pharmaceutica, N.V. | Alkylquinoline and alkylquinazoline kinase modulators |
| CA2617788A1 (en) * | 2005-08-04 | 2007-02-15 | Apogee Biotechnology Corporation | Sphingosine kinase inhibitors and methods of their use |
| WO2007053495A2 (en) * | 2005-11-01 | 2007-05-10 | Millennium Pharmaceuticals, Inc. | Compounds useful as antagonists of ccr2 |
| US8067415B2 (en) * | 2005-11-01 | 2011-11-29 | Millennium Pharmaceuticals, Inc. | Compounds useful as antagonists of CCR2 |
| WO2007053498A1 (en) * | 2005-11-01 | 2007-05-10 | Millennium Pharmaceuticals, Inc. | Compounds useful as antagonists of ccr2 |
| GB0524786D0 (en) * | 2005-12-05 | 2006-01-11 | Glaxo Group Ltd | Compounds |
| US7601844B2 (en) | 2006-01-27 | 2009-10-13 | Bristol-Myers Squibb Company | Piperidinyl derivatives as modulators of chemokine receptor activity |
| US7671062B2 (en) * | 2006-07-28 | 2010-03-02 | Bristol-Myers Squibb Company | Modulators of chemokine receptor activity, crystalline forms and process |
| US7687508B2 (en) * | 2006-07-28 | 2010-03-30 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
| US7629351B2 (en) * | 2006-07-28 | 2009-12-08 | Bristol-Myers Squibb Company | N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-2-oxo-3-(6-(trifluoromethyl)quinazolin-4-ylamino) pyrrolidin-1-yl)cyclohexyl)acetamide and other modulators of chemokine receptor activity, crystalline forms and process |
| US20080076120A1 (en) * | 2006-09-14 | 2008-03-27 | Millennium Pharmaceuticals, Inc. | Methods for the identification, evaluation and treatment of patients having CC-Chemokine receptor 2 (CCR-2) mediated disorders |
| CA2676352A1 (en) * | 2007-02-15 | 2008-08-21 | Pfizer Limited | Pharmaceutical compositions and methods for ccr5 antagonists |
| US20090324596A1 (en) | 2008-06-30 | 2009-12-31 | The Trustees Of Princeton University | Methods of identifying and treating poor-prognosis cancers |
| US10745701B2 (en) | 2007-06-28 | 2020-08-18 | The Trustees Of Princeton University | Methods of identifying and treating poor-prognosis cancers |
| US8178548B2 (en) | 2007-09-17 | 2012-05-15 | Abbott Laboratories | Anti-infective agents and uses thereof |
| EP2725015A1 (en) | 2007-09-17 | 2014-04-30 | AbbVie Bahamas Ltd. | Uracil or thymine derivative for treating hepatitis c |
| ES2368879T3 (es) | 2007-09-17 | 2011-11-23 | Abbott Laboratories | Pirimidinas antiinfecciosas y usos de las mismas. |
| CN101808515A (zh) * | 2007-09-25 | 2010-08-18 | 雅培制药有限公司 | 作为趋化因子受体拮抗剂的八氢并环戊二烯化合物 |
| TW201035100A (en) | 2008-12-19 | 2010-10-01 | Cephalon Inc | Pyrrolotriazines as ALK and JAK2 inhibitors |
| US8383812B2 (en) | 2009-10-13 | 2013-02-26 | Bristol-Myers Squibb Company | N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-A][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes |
| US8470820B2 (en) | 2010-01-22 | 2013-06-25 | Hoffman-La Roche Inc. | Nitrogen-containing heteroaryl derivatives |
| WO2011100227A1 (en) * | 2010-02-09 | 2011-08-18 | Bristol-Myers Squibb Company | Benzylpyrrolidinone derivatives as modulators of chemokine receptor activity |
| US9216952B2 (en) | 2010-03-23 | 2015-12-22 | Abbvie Inc. | Process for preparing antiviral compound |
| US8703768B2 (en) | 2010-06-09 | 2014-04-22 | Hoffmann-La Roche Inc. | Nitrogen containing heteroaryl compounds |
| EA030228B1 (ru) | 2010-07-16 | 2018-07-31 | ЭббВи Айэленд Анлимитед Компани | Фосфиновые лиганды для каталитических реакций |
| PH12013500105A1 (en) | 2010-07-16 | 2013-02-25 | Abbvie Bahamas Ltd | Process for preparing antiviral compounds |
| US8975443B2 (en) | 2010-07-16 | 2015-03-10 | Abbvie Inc. | Phosphine ligands for catalytic reactions |
| US9255074B2 (en) | 2010-07-16 | 2016-02-09 | Abbvie Inc. | Process for preparing antiviral compounds |
| PT2758371T (pt) * | 2011-09-19 | 2016-07-13 | Sigma Tau Ind Farmaceuti | Novos tio derivados que contêm lactamas como potentes inibidores de hdac e suas utilizações enquanto medicamentos |
| WO2013149376A1 (en) | 2012-04-02 | 2013-10-10 | Abbott Laboratories | Chemokine receptor antagonists |
| KR102283996B1 (ko) | 2013-03-15 | 2021-07-29 | 더 스크립스 리서치 인스티튜트 | 연골형성의 유도를 위한 화합물 및 방법 |
| WO2017004134A1 (en) * | 2015-06-29 | 2017-01-05 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| HUE064389T2 (hu) | 2016-04-29 | 2024-03-28 | Bayer Pharma AG | Az N-{6-(2-hidroxipropán-2-il)-2-[2-(metilszulfonil)etil]-2h-indazol-5-il}-6- (trifluormetil)piridin-2-karboxamid polimorf formája |
| CN109415339A (zh) | 2016-04-29 | 2019-03-01 | 拜耳医药股份有限公司 | N-[2-(3-羟基-3-甲基丁基)-6-(2-羟基丙-2-基)-2h-吲唑-5-基]-6-(三氟甲基)吡啶-2-甲酰胺的结晶形式 |
| EA202091751A1 (ru) | 2018-01-22 | 2020-11-06 | Бристол-Маерс Сквибб Компани | Композиции и способы лечения рака |
| EP3762380B1 (en) | 2018-03-05 | 2021-12-15 | Bristol-Myers Squibb Company | Phenylpyrrolidinone formyl peptide 2 receptor agonists |
| EP4192495A1 (en) | 2020-08-07 | 2023-06-14 | Bristol-Myers Squibb Company | Fgf21 combined with ccr2/5 antagonists for the treatment of fibrosis |
| CN112778109B (zh) * | 2021-01-15 | 2022-09-06 | 台州臻挚生物科技有限公司 | 1-[3-氯-5-(三氟甲基)苯基]-2,2,2-三氟乙酮及其衍生物的制备方法 |
| WO2023049796A1 (en) * | 2021-09-22 | 2023-03-30 | Drexel University | RelA/RSH INHIBITORS FOR THE TREATMENT OR PREVENTION OF MEDICAL BIOFILMS |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE812551C (de) * | 1949-05-13 | 1951-09-03 | Basf Ag | Verfahren zur Herstellung von Pyrrolidon-Derivaten |
| JPS6383082A (ja) | 1986-09-26 | 1988-04-13 | Takeda Chem Ind Ltd | テトラヒドロフランカルボン酸誘導体の製造法 |
| CA2084800A1 (en) | 1991-12-16 | 1993-06-17 | Joseph P. Vacca | Hiv protease inhibitors with an internal lactam ring |
| GB9515411D0 (en) | 1995-07-27 | 1995-09-27 | Pharmacia Spa | N-(4-substituted-benzyl)-2-aminolactam derivatives |
| US5827875A (en) | 1996-05-10 | 1998-10-27 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
| UA51716C2 (uk) | 1996-07-08 | 2002-12-16 | Авентіс Фармасьютікалз Продактс Інк. | Сполуки, що мають гіпотензивну, кардіопротекторну, анти-ішемічну та антиліполітичну властивості, фармацевтична композиція та способи лікування |
| US6054579A (en) | 1997-06-26 | 2000-04-25 | Leukosite, Inc. | Synthesis of substituted lactams |
| GB9716656D0 (en) | 1997-08-07 | 1997-10-15 | Zeneca Ltd | Chemical compounds |
| IL137517A0 (en) | 1998-01-27 | 2001-07-24 | Aventis Pharm Prod Inc | Substituted oxoazaheterocyclyl factor xa inhibitors |
| US6492553B1 (en) | 1998-01-29 | 2002-12-10 | Aventis Pharamaceuticals Inc. | Methods for preparing N-[(aliphatic or aromatic)carbonyl)]-2-aminoaetamide compounds and for cyclizing such compounds |
| CN1173946C (zh) | 1998-01-29 | 2004-11-03 | 阿温蒂斯药物公司 | 制备n-[(脂族或芳族)羰基]-2-氨基乙酰胺化合物和环化化合物的方法 |
| GB9803228D0 (en) | 1998-02-17 | 1998-04-08 | Zeneca Ltd | Chemical compounds |
| WO2000066551A1 (en) * | 1999-04-28 | 2000-11-09 | Takeda Chemical Industries, Ltd. | Cyclic amide compounds, process for the preparation of the same and uses thereof |
| WO2001017992A1 (en) | 1999-09-09 | 2001-03-15 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| BR0107532A (pt) | 2000-04-03 | 2004-11-03 | Bristol Myers Squibb Pharma Co | Composto, uso do composto, método para o tratamento de disfunções neurológicas associadas com a produção de b-amilóide, método de inibição da atividade de y-secretase e composição farmacêutica |
| EP1268434A1 (en) | 2000-04-03 | 2003-01-02 | Bristol-Myers Squibb Pharma Company | Cyclic lactams as inhibitors of a-beta protein production |
| MXPA02012712A (es) | 2000-06-30 | 2003-04-25 | Bristol Myers Squibb Pharma Co | N-ureidoheterocicloalquil-piperidinas como moduladores de la actividad del receptor de quimiocinas. |
| US6620823B2 (en) | 2000-07-11 | 2003-09-16 | Bristol-Myers Squibb Pharme Company | Lactam metalloprotease inhibitors |
| AR035773A1 (es) | 2000-12-20 | 2004-07-14 | Bristol Myers Squibb Pharma Co | Compuestos diamino ciclico, composicion farmaceutica y su uso en la fabricacion de un medicamento util para modular la actividad de una quimioquina |
| JP2005506949A (ja) | 2000-12-20 | 2005-03-10 | ブリストル−マイヤーズ・スクイブ・ファーマ・カンパニー | ケモカイン受容体の調節剤としてのジアミン |
| DE60209471D1 (de) | 2001-03-29 | 2006-04-27 | Topo Target As Copenhagen Koeb | Succinimid- und maleimidderivate und ihre verwendung als katalytische inhibitoren der topoisomerase ii |
| GB0114867D0 (en) | 2001-06-18 | 2001-08-08 | Merck Sharp & Dohme | Therapeutic agents |
| DE10135043A1 (de) | 2001-07-11 | 2003-01-30 | Bayer Cropscience Gmbh | Substituierte 3-Heteroaryl(amino- oder oxy)-pyrrolidin-2-one, Verfahren zu deren Herstellung und Verwendung als Herbizide oder als Pflanzenwachstumsregulatoren |
| EP1471715B1 (en) * | 2002-01-31 | 2010-01-13 | Kyocera Corporation | Cellular telephone |
| WO2003075853A2 (en) | 2002-03-08 | 2003-09-18 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
| TW200307667A (en) | 2002-05-06 | 2003-12-16 | Bristol Myers Squibb Co | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors |
| AU2003263393A1 (en) | 2002-09-04 | 2004-03-29 | Glenmark Pharmaceuticals Limited | New heterocyclic amide compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them |
| TW200508224A (en) | 2003-02-12 | 2005-03-01 | Bristol Myers Squibb Co | Cyclic derivatives as modulators of chemokine receptor activity |
| WO2004071449A2 (en) | 2003-02-12 | 2004-08-26 | Bristol-Myers Squibb Company | Lactams as modulators of chemokine receptor activity |
| US7230133B2 (en) | 2003-05-01 | 2007-06-12 | Bristol-Myers Squibb Company | Malonamides and malonamide derivatives as modulators of chemokine receptor activity |
| US7291615B2 (en) | 2003-05-01 | 2007-11-06 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
| US20050043392A1 (en) | 2003-08-21 | 2005-02-24 | Carter Percy H. | Lactams of alkylated acyclic diamine derivatives as modulators of chemokine receptor activity |
| US7378409B2 (en) | 2003-08-21 | 2008-05-27 | Bristol-Myers Squibb Company | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity |
| US7163937B2 (en) * | 2003-08-21 | 2007-01-16 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
| US7317019B2 (en) | 2003-08-21 | 2008-01-08 | Bristol Myers Squibb Co. | N-alkylated diaminopropane derivatives as modulators of chemokine receptor activity |
-
2004
- 2004-08-19 US US10/923,619 patent/US7163937B2/en not_active Expired - Lifetime
- 2004-08-20 AU AU2004268968A patent/AU2004268968B2/en not_active Ceased
- 2004-08-20 EP EP04781806.7A patent/EP1656345B1/en not_active Expired - Lifetime
- 2004-08-20 ES ES04781806.7T patent/ES2437104T3/es not_active Expired - Lifetime
- 2004-08-20 RU RU2006108867/04A patent/RU2006108867A/ru not_active Application Discontinuation
- 2004-08-20 SI SI200432117T patent/SI1656345T1/sl unknown
- 2004-08-20 JP JP2006524092A patent/JP4795238B2/ja not_active Expired - Fee Related
- 2004-08-20 CA CA2536384A patent/CA2536384C/en not_active Expired - Fee Related
- 2004-08-20 KR KR1020067003442A patent/KR101120338B1/ko not_active Expired - Fee Related
- 2004-08-20 RS YUP-2006/0116A patent/RS20060116A/sr unknown
- 2004-08-20 DK DK04781806.7T patent/DK1656345T3/da active
- 2004-08-20 NZ NZ545317A patent/NZ545317A/en not_active IP Right Cessation
- 2004-08-20 HR HRP20131048TT patent/HRP20131048T1/hr unknown
- 2004-08-20 WO PCT/US2004/027196 patent/WO2005021500A1/en not_active Ceased
- 2004-08-20 BR BRPI0413713-2A patent/BRPI0413713A/pt not_active IP Right Cessation
- 2004-08-20 PT PT47818067T patent/PT1656345E/pt unknown
- 2004-08-20 PL PL04781806T patent/PL1656345T3/pl unknown
- 2004-08-20 MX MXPA06001819A patent/MXPA06001819A/es active IP Right Grant
-
2006
- 2006-02-14 NO NO20060717A patent/NO335946B1/no not_active IP Right Cessation
- 2006-02-20 IS IS8313A patent/IS8313A/is unknown
- 2006-02-20 IL IL173824A patent/IL173824A/en not_active IP Right Cessation
- 2006-10-10 US US11/545,415 patent/US7482335B2/en not_active Expired - Lifetime
-
2009
- 2009-01-15 US US12/354,258 patent/US7829571B2/en not_active Expired - Lifetime
-
2013
- 2013-10-08 IL IL228794A patent/IL228794A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007502843A5 (enExample) | ||
| RU2006108867A (ru) | Модуляторы активности рецептора хемокина | |
| JP7357135B2 (ja) | ピリダジノン化合物およびその使用 | |
| ES2244231T3 (es) | Derivados de aminopirazol. | |
| KR101078505B1 (ko) | 질소 함유 복소환 유도체 및 이들을 유효 성분으로 하는약제 | |
| ES2524787T3 (es) | Derivados de piridazinona como inhibidores de PARP | |
| WO1991019697A1 (fr) | Derive de pyridine avec antagonisme de l'angiotensine ii | |
| CZ20023777A3 (cs) | Farmaceuticky aktivní piperidinové deriváty, zvláště jako modulátory receptoru chemokinu | |
| WO1988002365A1 (fr) | Derives d'amines cycliques | |
| ES2362214T3 (es) | Indazoles sustituidos con amida como inhibidores de poli(adp-ribosa)polimerasa (parp). | |
| JP2006508065A5 (enExample) | ||
| JP2001521934A5 (enExample) | ||
| WO2001021615A1 (fr) | Dérivés de benzimidazole | |
| WO2002088122A1 (en) | Heterocyclic compounds | |
| WO2005044192A2 (en) | Triazole compounds and uses related thereto | |
| TW200829585A (en) | Cyclohexenyl-aryl compounds for inflammation and immune-related uses | |
| CA2569654A1 (en) | Benzimidazolone carboxylic acid derivatives | |
| JP2005510522A (ja) | ピペリジン誘導体およびケモカイン・レセプター（特にｃｃｒ５）活性モジュレーターとしてのその使用 | |
| CZ20023243A3 (cs) | Pyrrolidinové deriváty, způsob jejich výroby, jejich pouľití a farmaceutický prostředek | |
| JPH0557983B2 (enExample) | ||
| JP2005511621A (ja) | ケモカインレセプターの調節物質としての新規ピペリジン誘導体 | |
| DE69333489T2 (de) | Heterocyclische Verbindungen und ihre Verwendung als Angiotensin II Antagonisten | |
| WO2003018549A2 (en) | Bicyclic compounds as inhibitors of chemokine binding to us28 | |
| JP2004524359A (ja) | ケモカインレセプターのモジュレーターとしての新規ピペリジン誘導体 | |
| JP2018502075A (ja) | 抗ヒスタミン剤としての新規ベンゾイミダゾール誘導体 |